Neuroblastoma

Clinical Trials

Mayo Clinic is a member of the Children's Oncology Group (COG), the national cooperative group for clinical trials and basic science investigation of childhood cancers. Mayo participates actively in COG trials to provide state-of-the-art clinical trials to children with cancer.

The Division of Pediatric Hematology/Oncology at Mayo Clinic is a member of a consortium of cancer centers across the United States established by the National Cancer Institute (NCI) as Phase I investigational centers. These institutions study and develop cutting-edge technologies and protocols for the successful treatment of neuroblastoma and other childhood cancers. Mayo specialists have access to experimental agents and new, investigational drugs as soon as these treatments are available. Phase I trials are utilized for patients whose tumors have recurred after standard therapy has failed.

Below is a list of Neuroblastoma clinical trials from the clinical trials database at Mayo Clinic.

Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
OBJECTIVES: - Evaluate the factors currently used for risk-group assignment (DNA content, MYCN copy number, and tumor histology) in patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. - Assess the prevalence of 1p, 11q, 14q loss of heterozygosity and gain of 17q; the expression of nerve growth factor and its high affinity (Trk-A) and low affinity (p75^NTR) receptors; and telomerase activity in these patients.
Read more

Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
OBJECTIVES: - Collect brain tumor tissue and an accompanying blood sample from pediatric patients with brain tumors treated at Children's Oncology Group institutions. - Provide a repository for long-term storage of specimens from these patients.
Read more

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
OBJECTIVES: Primary - Determine if treatment of pediatric patients with newly diagnosed supratentorial primitive neuroectodermal CNS tumors or high-risk medulloblastoma with intensive induction chemotherapy comprising vincristine, etoposide, cyclophosphamide, and cisplatin in combination with high-dose methotrexate and leucovorin calcium followed by consolidation chemotherapy comprising carboplatin and thiotepa and peripheral blood stem cell rescue results in a higher complete response rate then in patients treated with the
Read more

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
OBJECTIVES: Primary - To improve the 3-year event-free survival (EFS) rate of high-risk neuroblastoma patients through treatment with a tandem consolidation of thiotepa/cyclophosphamide followed by carboplatin/etoposide/melphalan (CEM) as compared to single CEM consolidation.
Read more

Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma
OBJECTIVES: Primary - Compare the event-free survival of patients with neuroblastoma who have completed myeloablative therapy and autologous stem cell transplantation (ASCT) when treated with adjuvant isotretinoin with or without monoclonal antibody Ch14.18,
Read more